Furthermore, in the hippocampus, evodiamine significantly reduces neuroinflammation (TNF-α, IL-1β, and IL-6) and glial cell activation, rendering it a potential treatment for neurodegenerative diseases such as Alzheimer's disease (Wang et al., 2018). The gene discussed is TNF; the disease is early-onset autosomal dominant Alzheimer disease.